Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
Eliem Therapeutics, Inc. (Nasdaq: ELYM) announced that CEO Bob Azelby will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference on December 1, 2022, at 11:40 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eliem Therapeutics, Inc. (Nasdaq: ELYM) announced that CEO Bob Azelby will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference on December 1, 2022, at 11:40 AM ET. The conference aims to highlight the company’s focus on developing novel therapies for neuronal excitability disorders, addressing unmet needs in areas such as psychiatry and epilepsy. A live webcast of the presentation will be accessible through the Investors section of Eliem's website, with an archived replay available for 30 days post-conference.
Positive
- Eliem Therapeutics focuses on a high-need area in biotechnology with therapies for neuronal excitability disorders.
- CEO Bob Azelby will represent the company at a significant healthcare conference, enhancing visibility.
Negative
- None.
Details
News Market Reaction – ELYM
The recorded move for ELYM in the trading session of this news was -5.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.
A live webcast will be available on the Investors section of the Eliem Therapeutics website at https://www.eliemtx.com. An archived replay will remain available on Eliem’s website for at least 30 days after the conference.
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843
Media
Marites Coulter
Verge Scientific
Mcoulter@vergescientific.com
415.819.2214
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.